373 reports of this reaction
2.1% of all FORMOTEROL FUMARATE reports
#9 most reported adverse reaction
GASTROOESOPHAGEAL REFLUX DISEASE is the #9 most commonly reported adverse reaction for FORMOTEROL FUMARATE, manufactured by Alembic Pharmaceuticals Inc.. There are 373 FDA adverse event reports linking FORMOTEROL FUMARATE to GASTROOESOPHAGEAL REFLUX DISEASE. This represents approximately 2.1% of all 18,067 adverse event reports for this drug.
Patients taking FORMOTEROL FUMARATE who experience gastrooesophageal reflux disease should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
GASTROOESOPHAGEAL REFLUX DISEASE is a less commonly reported adverse event for FORMOTEROL FUMARATE, but still significant enough to appear in the safety profile.
In addition to gastrooesophageal reflux disease, the following adverse reactions have been reported for FORMOTEROL FUMARATE:
The following drugs have also been linked to gastrooesophageal reflux disease in FDA adverse event reports:
GASTROOESOPHAGEAL REFLUX DISEASE has been reported as an adverse event in 373 FDA reports for FORMOTEROL FUMARATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
GASTROOESOPHAGEAL REFLUX DISEASE accounts for approximately 2.1% of all adverse event reports for FORMOTEROL FUMARATE, making it a notable side effect.
If you experience gastrooesophageal reflux disease while taking FORMOTEROL FUMARATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.